GF Fund Management’s Cullinan Oncology CGEM Stock Holding History

GF Fund Management’s Portfolio CGEM Stock Details CGEM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$20.9K	Buy	1,360 +108	+9%	+$2.07K	﹤0.01%	490
2026 Q2	$22.8K	Sell	1,252 -66	-5%	-$980	﹤0.01%	474
2026 Q1	$18.7K	Buy	1,318 +158	+14%	+$2.03K	﹤0.01%	506
2025 Q4	$12K	Sell	1,160 -91	-7%	-$821	﹤0.01%	563
2025 Q3	$7.42K	Sell	1,251 -240	-16%	-$1.76K	﹤0.01%	577
2025 Q2	$11.2K	Hold	1,491	–	–	﹤0.01%	559
2025 Q1	$11.3K	Buy	1,491 +268	+22%	+$2.57K	﹤0.01%	549
2024 Q4	$14.9K	Buy	+1,223	New	+$17.6K	﹤0.01%	497

Other funds holding CGEM

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return

Fisher Asset Management Camas, Washington $348B AUM 26.9% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $362B AUM 34.89% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return

Connor, Clark & Lunn Investment Management (CC&L) Vancouver, British Columbia, Canada $57.2B AUM 42.49% 1-Year Est. Return

UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return

Barclays London, United Kingdom $500B AUM 36.84% 1-Year Est. Return

Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return

Nuveen Charlotte, North Carolina $420B AUM 34.97% 1-Year Est. Return

GF Fund Management's CGEM Position: Q3 2026 in Review

GF Fund Management increased its Cullinan Oncology (CGEM) stake by 8.6% in Q3 2026, buying an estimated $2.07K and bringing the position to 1,360 shares worth $20.9K. The position accounts for ﹤0.01% of the portfolio, ranked #490.

GF Fund Management first reported a position in CGEM in Q4 2024 and has held it in 8 quarters since. The position peaked at $22.8K in Q2 2026. 72 funds tracked by Wall St. Rank hold CGEM as of Q3 2026.

GF Fund Management held 1,360 shares of Cullinan Oncology worth $20.9K as of Q3 2026.
GF Fund Management bought 108 Cullinan Oncology shares in Q3 2026, an estimated $2.07K.
Cullinan Oncology made up ﹤0.01% of GF Fund Management's portfolio in Q3 2026, its #490 holding.
GF Fund Management first reported a position in Cullinan Oncology in Q4 2024 and has held it in 8 quarters since.
GF Fund Management's Cullinan Oncology position peaked at $22.8K in Q2 2026.
72 funds tracked by Wall St. Rank held Cullinan Oncology as of Q3 2026.

Based on GF Fund Management's 13F filing for Q3 2026, filed 26 Oct 2026.